Compare GETY & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | BNTC |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.7M | 405.7M |
| IPO Year | N/A | 2020 |
| Metric | GETY | BNTC |
|---|---|---|
| Price | $0.74 | $10.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.01 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 1.6M | 125.8K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.64 | N/A |
| Revenue Next Year | $2.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $9.85 |
| 52 Week High | $3.21 | $17.15 |
| Indicator | GETY | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 19.23 | 39.21 |
| Support Level | $1.07 | $9.85 |
| Resistance Level | $1.22 | $11.55 |
| Average True Range (ATR) | 0.10 | 0.73 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 3.10 | 31.19 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.